Cathepsin K in the immunohistochemical diagnosis of melanocytic lesions

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 3, 2014, Pages 1132-1139

  Rao, Qiu ^a   Wang, Yan ^b   Xia, Qiu Yuan ^a   Shi, Shan Shan ^a   Shen, Qin ^a   Tu, Pin ^a   Shi, Qun Li ^a   Zhou, Xiao Jun ^a   Wu, Bo ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Cathepsin K; Immunohistochemistry; Melanocytic lesions; Melanoma; MITF; Nevi

Indexed keywords

CATHEPSIN K; TUMOR MARKER;

BIOSYNTHESIS; DIAGNOSTIC USE; HUMAN; IMMUNOHISTOCHEMISTRY; MELANOMA; METABOLISM; NEVUS; SKIN NEOPLASMS;

CATHEPSIN K; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; NEVUS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84899519077     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Busam KJ, Iversen K, Coplan KC and Jungbluth AA. Analysis of microphthalmia transcription factor expression in normal tissues and tumors, and comparison of its expression with S-100 protein, gp100, and tyrosinase in desmoplastic malignant melanoma. Am J Surg Pathol 2001; 25: 197-204.
2. Clarkson KS, Sturdgess IC and Molyneux AJ. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A). J Clin Pathol 2001; 54: 196-200.
3. King R, Googe PB, Weilbaecher KN, Mihm MC Jr and Fisher DE. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors. Am J Surg Pathol 2001; 25: 51-57.
4. Miettinen M, Fernandez M, Franssila K, Gatalica Z, Lasota J and Sarlomo-Rikala M. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers. Am J Surg Pathol 2001; 25: 205-211.
5. Xu X, Chu AY, Pasha TL, Elder DE and Zhang PJ. Immunoprofile of MITF, tyrosinase, melan-A, and MAGE-1 in HMB45-negative melanomas. Am J Surg Pathol 2002; 26: 82-87.
6. Krishna M. Diagnosis of metastatic neoplasms: an immunohistochemical approach. Arch Pathol Lab Med 2010; 134: 207-215.
7. Nielsen PS, Riber-Hansen R and Steiniche T. Immunohistochemical double stains against Ki67/MART1 and HMB45/MITF: promising diagnostic tools in melanocytic lesions. Am J Dermatopathol 2011; 33: 361-370.
8. Motyckova G, Weilbaecher KN, Horstmann M, Rieman DJ, Fisher DZ and Fisher DE. Linking osteopetrosis and pycnodysostosis: regulation of cathepsin K expression by the microphthalmia transcription factor family. Proc Natl Acad Sci U S A 2001; 98: 5798-5803.
9. Davis IJ and Fisher DE. MiT transcription factor associated malignancies in man. Cell Cycle 2007; 6: 1724-1729.
10. Haq R and Fisher DE. Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer. J Clin Oncol 2011; 29: 3474-3482.
11. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE and Sellers WR. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005; 436: 117-122.
12. Stark M and Hayward N. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res 2007; 67: 2632-2642.
13. Cronin JC, Wunderlich J, Loftus SK, Prickett TD, Wei X, Ridd K, Vemula S, Burrell AS, Agrawal NS, Lin JC, Banister CE, Buckhaults P, Rosenberg SA, Bastian BC, Pavan WJ and Samuels Y. Frequent mutations in the MITF pathway in melanoma. Pigment Cell Melanoma Res 2009; 22: 435-444.
14. Righi A, Dimosthenous K and Rosai J. PEComa: another member of the MiT tumor family? Int J Surg Pathol 2008; 16: 16-20.
15. Argani P, Aulmann S, Illei PB, Netto GJ, Ro J, Cho HY, Dogan S, Ladanyi M, Martignoni G, Goldblum JR and Weiss SW. A distinctive subset of PEComas harbors TFE3 gene fusions. Am J Surg Pathol 2010; 34: 1395-1406.
16. Dickson BC, Brooks JS, Pasha TL and Zhang PJ. TFE3 Expression in Tumors of the Microphthalmia-Associated Transcription Factor (MiTF) Family. Int J Surg Pathol 2011; 19: 26-30.
17. Rao Q, Chen JY, Wang JD, Ma HH, Zhou HB, Lu ZF and Zhou XJ. Renal cell carcinoma in children and young adults: clinicopathological, immunohistochemical, and VHL gene analysis of 46 cases with follow-up. Int J Surg Pathol 2011; 19: 170-179.
18. Inamura K, Fujiwara M, Togashi Y, Nomura K, Mukai H, Fujii Y, Yamamoto S, Yonese J, Fukui I and Ishikawa Y. Diverse fusion patterns and heterogeneous clinicopathologic features of renal cell carcinoma with t(6;11) translocation. Am J Surg Pathol 2012; 36: 35-42.
19. Rao Q, Liu B, Cheng L, Zhu Y, Shi QL, Wu B, Jiang SJ, Wang Y, Wang X, Yu B, Zhang RS, Ma HH, Lu ZF, Tu P, Wang JD and Zhou XJ. Renal cell carcinomas with t(6;11)(p21;q12): A clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization. Am J Surg Pathol 2012; 36: 1327-1338.
20. Argani P, Yonescu R, Morsberger L, Morris K, Netto GJ, Smith N, Gonzalez N, Illei PB, Ladanyi M and Griffin CA. Molecular confirmation of t(6;11)(p21;q12) renal cell carcinoma in archival paraffin-embedded material using a break-apart TFEB FISH assay expands its clinicopathologic spectrum. Am J Surg Pathol 2012; 36: 1516-1526.
21. Rao Q, Williamson SR, Zhang S, Eble JN, Grignon DJ, Wang M, Zhou XJ, Huang W, Tan PH, Maclennan GT and Cheng L. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum. Am J Surg Pathol 2013; 37: 804-815.
22. Williamson SR, Bunde PJ, Montironi R, Lopez-Beltran A, Zhang S, Wang M, Maclennan GT and Cheng L. Malignant Perivascular Epithelioid Cell Neoplasm (PEComa) of the Urinary Bladder With TFE3 Gene Rearrangement: Clinicopathologic, Immunohistochemical, and Molecular Features. Am J Surg Pathol 2013; 37: 1619-1626.
23. Rao Q, Cheng L, Xia QY, Liu B, Li L, Shi QL, Shi SS, Yu B, Zhang RS, Ma HH, Lu ZF, Tu P and Zhou XJ. Cathepsin K expression in a wide spectrum of perivascular epithelioid cell neoplasms (PEComas): a clinicopathological study emphasizing extrarenal PEComas. Histopathology 2013; 62: 642-650.
24. Martignoni G, Pea M, Gobbo S, Brunelli M, Bonetti F, Segala D, Pan CC, Netto G, Doglioni C, Hes O, Argani P and Chilosi M. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas. Mod Pathol 2009; 22: 1016-1022.
25. Martignoni G, Bonetti F, Chilosi M, Brunelli M, Segala D, Amin MB, Argani P, Eble JN, Gobbo S and Pea M. Cathepsin K expression in the spectrum of perivascular epithelioid cell (PEC) lesions of the kidney. Mod Pathol 2012; 25: 100-111.
26. Rao Q, Zhang XM, Tu P, Xia QY, Shen Q, Zhou XJ and Shi QL. Renal cell carcinomas with t(6;11)(p21;q12) presenting with tubulocystic renal cell carcinoma-like features. Int J Clin Exp Pathol 2013; 6: 1452-1457.
27. Xia QY, Rao Q, Shen Q, Shi SS, Li L, Liu B, Zhang J, Wang YF, Shi QL, Wang JD, Ma HH, Lu ZF, Yu B, Zhang RS and Zhou XJ. Oncocytic papillary renal cell carcinoma: a clinicopathological study emphasizing distinct morphology, extended immunohistochemical profile and cytogenetic features. Int J Clin Exp Pathol 2013; 6: 1392-1399.
28. Martignoni G, Gobbo S, Camparo P, Brunelli M, Munari E, Segala D, Pea M, Bonetti F, Illei PB, Netto GJ, Ladanyi M, Chilosi M and Argani P. Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions. Mod Pathol 2011; 24: 1313-1319.
29. Buhling F, Reisenauer A, Gerber A, Kruger S, Weber E, Bromme D, Roessner A, Ansorge S, Welte T and Rocken C. Cathepsin K-a marker of macrophage differentiation? J Pathol 2001; 195: 375-382.
30. Reghellin D, Poletti V, Tomassett S, Dubini A, Cavazza A, Rossi G, Lestani M, Pedron S, Daniele I, Montagna L, Murer B and Chilos M. Cathepsin-K is a sensitive immunohistochemical marker for detection of micro-granulomas in hypersensitivity pneumonitis. Sarcoidosis Vasc Diffuse Lung Dis 2010; 27: 57-63.
31. Bundscherer A, Hafner C, Maisch T, Becker B, Landthaler M and Vogt T. Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines. Oncol Rep 2008; 19: 547-553.
32. Karbowniczek M, Spittle CS, Morrison T, Wu H and Henske EP. mTOR is activated in the majority of malignant melanomas. J Invest Dermatol 2008; 128: 980-987.
33. Soon CW, Algazi AP, Cha EN and Daud AI. New horizons in melanoma treatment: targeting molecular pathways. Ochsner J 2010; 10: 93-98.
34. Kneissel M, Luong-Nguyen NH, Baptist M, Cortesi R, Zumstein-Mecker S, Kossida S, O'Reilly T, Lane H and Susa M. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. Bone 2004; 35: 1144-1156.
35. Le Gall C, Bonnelye E and Clezardin P. Cathepsin K inhibitors as treatment of bone metastasis. Curr Opin Support Palliat Care 2008; 2: 218-222.
36. Clezardin P. Therapeutic targets for bone metastases in breast cancer. Breast Cancer Res 2011; 13: 207.